

Charity registration number 1163211

Company registration number CE004367 (England and Wales)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

PARKINSON'S EUROPE

(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	G Boyle J M M Domingos C P Likar A Moretti A S Butler B J Magennis K Wouters J Sinclair E Ildal C Molohan C Bale	(Appointed 26 June 2024) (Appointed 26 June 2024) (Appointed 26 June 2024) (Appointed 26 June 2024)
Key Personnel	Rusell Patten Dominic Graham Lisa Wong	Director General Operations Director Finance Manager
Charity number	1163211	
Company number	CE004367	
Registered office	Lynwood House Crofton Road Orpington Kent BR6 8QE	
Independent examiner	Louise Hallsworth, FCA Baxter & Co Chartered Accountants Lynwood House, Crofton Road Orpington Kent BR6 8QE	

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) CONTENTS

	Page
Trustees' report	1 - 7
Independent examiner's report	8
Statement of financial activities	9 - 10
Balance sheet	11
Notes to the financial statements	12 - 20

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's constitution, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

The objectives are to promote and protect the physical and mental health of those suffering from Parkinson's disease. In particular, but not limited to the following:

- 1) to challenge existing mind-sets, shift attitudes and remove the hurdles that prevent the people with Parkinson's from receiving early and appropriate treatment and individualised care;
- 2) to increase public and political awareness of Parkinson's;
- 3) to help reduce stigma and remove discrimination against people with Parkinson's.

Public benefit

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

Achievements and performance

Significant activities and achievements against objectives

Our New Four-Year Strategy (2025-2028)

In 2024, we were at the end of our previous (2019-2024) strategy window. Through evaluating all the data we had collected about the needs and wants of our stakeholders, we decided we needed a significant overhaul of the old strategy. The purpose was to really focus and deliver on what our stakeholders had told us they wanted.

The new strategy development started in February 2024, but the collection and review of supporting data had been ongoing since 2022, and involved internal and external stakeholders from the Parkinson's community. Our new four-year strategy was launched in January 2025 and is available via our website in five languages.

World Parkinson's Day 2024

Every year, World Parkinson's Day (WPD) on 11 April provides us with a unique opportunity to capture the world's attention with a far greater impact than usual. As founders of World Parkinson's Day, we feel it's our responsibility to lead the way, creating one of the biggest campaigns globally to create awareness and shine a spotlight on the needs of people with Parkinson's – as well as supporting and amplifying our Member Organisations' campaigns to a wider audience.

We decided this year to create a campaign that would prolong this global impact far beyond WPD itself, using the day to launch a six-month campaign we called the Parkinson's Summer of Sport. This campaign was about raising awareness of the benefits of exercise for people with Parkinson's, helping people to find an exercise that's right for them, and giving advice on overcoming exercise barriers.

Parkinson's Engagement Network

Parkinson's Europe recognised the need to reach more people across Europe in a strategic and constructive way, to share calls to action that would help us achieve our current and future strategic activities and support the many significant advancements for the Parkinson's community that are continually taking place in different areas. Built with financial support from our partner IQVIA and launched in December 2023, the PEN is an online network designed to involve people from Europe (and beyond) in Parkinson's-related activities. The PEN will help communicate better about Parkinson's opportunities to people interested and help get more people involved.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Our Attendance at Events, Panels and Symposiums

Attending international events, congresses, panels and symposiums has always been a key priority for Parkinson's Europe. In 2024, our President Josefa Domingos, our Director General Russell Patten and our Strategic Director Amelia Hursey attended the following events:

- International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD), Lisbon, Portugal, March 2024 – attendee and speaker
- Ace Clinical Trials Summit, London, UK, March 2024 – speaker and session chair
- Digital Health @ Reuters Events: Pharma 2024, Barcelona, Spain, April 2024 – co-presenting session
- European Patients' Forum (EPF) Annual General Meeting, Brussels, Belgium, April 2024 – attendee
- Outsourcing in Clinical Trials (OCT) Europe, Barcelona, Spain, May 2024 – speaker and panelist
- International Association of Parkinsonism and Related Disorders (IAPRD) World Congress, Lisbon, Portugal, May 2024 – attendee
- Patient Engagement Open Forum (PEOF), Baveno, Italy, May 2024 – attendee
- Patients as Partners Europe, London, UK, May 2024 – attendees
- Congress of the European Academy of Neurology (EAN), Helsinki, Finland, June-July 2024 – attendee
- EUPATI Annual General Meeting, Brussels, Belgium, September 2024 – moderator
- International Congress of Parkinson's Disease and Movement Disorders (MDS), Philadelphia, USA, September-October 2024 – booth
- European Medicines Agency Accelerating Clinical Trials in the EU (ACT-EU) annual meeting, Amsterdam, the Netherlands, October 2024 – moderator
- Online Order and Home Delivery of Medicines (OnHOME) Alliance launch event, Brussels, Belgium, October 2024 – panelist
- First European Non-Pharmacological Intervention Society (NPIS) Forum, Brussels, Belgium, December 2024 – speaker.

Our New Website

Following a major redesign project in the latter half of 2023, our brand-new website went live in March 2024. The new website allows our audience to benefit from:

- much improved navigation, helping people to find the information they need quickly;
- an interactive map for users to easily find Parkinson's events, organisations and initiatives in their country;
- a new and improved home for our online magazine Parkinson's Life, with more regular articles, stories and podcasts;
- an exclusive Members area filled with useful tools and resources for our Member Organisations.

We have continued to add new features and updates to our website over the course of 2024. Results included:

- 300,000 views since the site launched, including users from every European country;
- a 91% engagement rate (which is a 57% increase on the old site);
- hundreds of new pins added to our map, including 50 for World Parkinson's Day covering 25 countries;
- 80 new articles on Parkinson's Life (an 80% increase on our pre-launch numbers), covering stories from 19 European countries (a 73% increase on last year).

Our special thanks go to the following organisations who contributed to the funding of our new website:

- Boston Scientific Foundation Europe
- Bial
- Britannia
- Merz Therapeutics
- Novartis
- Roche
- Servier
- UCB

Our Increased Social Media Presence

In 2024, we wanted to build on our success from 2023, where we grew our social audience by 20%. This is necessary in order to reach more people with Parkinson's who need help and information, to support our Member Organisations and partners in achieving a higher visibility, reach and impact – and to position Parkinson's Europe as a fundamental part of the digital Parkinson's community.

PARKINSON'S EUROPE

(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

Throughout the year, people with Parkinson's and our Member Organisations provided moving, authentic and engaging stories for our campaigns and video content. Among others, we collaborated with artist Barbara Salsberg Mathews on her new book, *What Parkinson's Feels Like*: we used social media and other channels to crowdsource contributions to the book, and we launched the book on our website and social media. It has had more than 600 downloads, and helped to raise thousands of pounds in charity donations.

We also worked with our treatment industry partners on important awareness campaigns on topics such as DBS surgery, OFF periods, and Parkinson's care pathways.

Our Enhanced Newsletter

Our 2024 communications strategy has seen us growing our audience and engagement across every channel. We achieved the following results regarding our email marketing:

- We grew our general e-shot audience by 21% to over 4,100.
- We increased our open rate by 5% to almost 49%.
- We established a purpose-driven email campaign schedule, sending regular e-shots highlighting our core campaigns and top content.
- We redesigned our email templates in line with our new branding.
- We increased the visibility of our newsletter to expand our subscriber base – for instance adding a sign-up box on our website homepage, on relevant campaign landing pages, and on our LinkTree profile.

Members Outreach and Support

We have worked hard to support our Member Organisations in 2024, and are pleased to say we've shared a very productive year with all of them.

A number of memorable events have been held by our members this year, and we have been proud to play a part in supporting them in different ways:

- Parkinson Italia's Parkinson's disease – strategies for the future event took place in Rome, in March.
- We introduced our industry partner IQVIA to national Parkinson's organisations in Nordic countries at the start of the year.
- In autumn, we supported events such as Parkinson's UK's 2-day Par-Con and France Parkinson's first Parlons Recherche event, promoting the events across our website, member e-shots and social media platforms.
- We also made a donation to Društvo Trepetlika, helping the Slovenian organisation host the Ping Pong Parkinson World Championship in Laško in October.
- Strategic Director Amelia Hursey was able to host some members for a networking dinner at the International Congress of Parkinson's Disease and Movement Disorders (MDS), Philadelphia, USA, in September.

Parkinson's Europe was pleased to welcome two new member organisations this year:

- PAR.KIN.S.O.N. (Greece)
- the Catalan Parkinson's Association (Spain)

A new benefit of membership introduced in 2024 is an interview on Parkinson's Life, allowing new member organisations to introduce themselves, tell the story of their organisation, and share their work with the wider European Parkinson's community. Examples include our interviews with PAR.KIN.S.O.N., the Catalan Parkinson's Association and Cure4Parkinson in Denmark.

Finally, an exclusive members-only section launched on our new website in the spring. Members can now log in to access advocacy toolkits, exclusive travel discounts and more, and we will be adding some exciting new developments to this area in 2025.

PARKINSON'S EUROPE (FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION) TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Collaboration with the Treatment Industry

Parkinson's Europe has a 30-year history of positive and fruitful collaboration with the treatment industry – a key stakeholder in the Parkinson's community and a key player in the development of new treatments – and hopefully a cure – for Parkinson's.

Parkinson's Europe would like to sincerely thank the following treatment industry partners for providing funding and support to our activities in 2024:

- Abbott
- AbbVie
- Bial
- Biogen
- Boston Scientific
- Britannia Pharmaceuticals
- Centogene
- Charco Neurotech
- ConvaTec
- Esteve
- Insightec
- IQVIA
- Lundbeck
- Medtronic
- Merz
- Nordic InfuCare
- Novartis
- Parexel
- Roche
- Servier
- UCB
- Zambon

Working Group on Device-Assisted Therapies

In 2024, the group worked together to develop a knowledge-sharing resource aimed at people with Parkinson's and their families to increase their awareness of DATs and empower them to discuss these therapy options with healthcare professionals. All members of the working group contributed their knowledge, expertise and available materials. An initial draft of this knowledge-sharing resource was developed in 2024, and will be launched in the first half of 2025.

Online Campaign on Deep Brain Stimulation and Surgery

In 2024, we invited the three main DBS industry companies (Abbott, Boston Scientific and Medtronic) to support an online multimedia, multi-language campaign aimed at an honest, comprehensive and clear picture of the main aspects to take into account when considering DBS surgery – demystifying common fears and misconceptions but also objectively considering common challenges and critical aspects, with the goal to empower people with Parkinson's to discuss these topics with healthcare professionals and make more informed treatment choices.

In 2024, as part of the campaign we developed:

- a Parkinson's Life article:
 - published in five languages
 - achieved more than 95,000 views
- a set of social media infographics
 - published in five languages
 - achieved nearly 8 million impressions and nearly 30,000 engagements
- a Parkinson's life podcast episode
 - achieved more than 600 downloads by the end of the year.

PARKINSON'S EUROPE

(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

The campaign assets were published and disseminated via our website, newsletter and social media channels, and supported via paid promotion. Nearly 8 million impressions and a very high engagement rate make this the most successful Parkinson's Europe campaign so far.

The campaign will continue in 2025 with the production of video testimonies, a social media quiz and a webinar.

Online Campaign on Parkinson's OFF Periods

OFF periods are among the most important symptoms of Parkinson's, affecting the majority of people living with the condition and significantly impacting people's wellbeing and social life – as well as those of their family members and caregivers.

In late 2023 and early 2024, we launched an online awareness campaign supported by our industry partner Bial, aimed at raising awareness of the impact of Parkinson's OFF periods, informing people about how to recognise and anticipate them, as well as about available treatment options. As part of this campaign, we developed:

- a Parkinson's Life article
- a set of social media infographics
- a set of video testimonials

The campaign was very successful, with nearly 250,000 impressions and a very high engagement rate. In 2024, we invited our industry partner companies Bial and Esteve to support an extension of the campaign, with the goal of translating the campaign content into several languages and further disseminating it to a broader European audience.

The translated campaign assets were developed in 2024 and will be launched and disseminated in 2025.

Information and Awareness about Disease-Modifying Therapies

In 2024, Parkinson's Europe worked with our industry partners UCB and Novartis around the development of an information and awareness campaign about DMTs. By being involved in several advisory boards and review activities (which involved other important international stakeholders such as Parkinson's UK and the Michael J Fox Foundation), we contributed extensively to the development of a clear and consistent narrative and set of main messages on the

This important information will be translated and disseminated to the Parkinson's community, with the involvement of national Parkinson's organisations, as part of a multi-media awareness campaign in 2025.

Addressing Barriers to Care for People with Advanced Parkinson's – Call to Action

In January 2024, Parkinson's Europe and our industry partner AbbVie co-hosted a roundtable on the topic of care pathways for people with advanced Parkinson's. Expert panelists from different European countries – movement disorder specialists, nurses, researchers, people with Parkinson's and representatives of Parkinson's organisations – gave insights about barriers and best practices around care pathways for advanced Parkinson's, highlighting gaps and common areas for improvement and identifying possible solutions. The main findings of this roundtable were published into a report and an infographic.

Following the success of the roundtable, we have been working with AbbVie and other important stakeholders (the European Federation of Neurological Association, EFNA, and the International Parkinson and Movement Disorder Society European Section, MDS-ES) in the development of a joint call to action aimed at European policymakers – calling for a commitment to improving healthcare services for people with Parkinson's and a pledge to make progress in the following three key areas:

- the recruitment and retention of essential healthcare workforce
- the formalisation of neurodegenerative nurses in healthcare systems
- access to innovation to optimise healthcare resources.

The call to action was launched on 29 November 2024 (World Movement Disorders Day), and endorsed by 11 European Parkinson's organisations. In 2025, we will work on a series of awareness activities to leverage this call to action and call for better healthcare for people with Parkinson's in Europe.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

Financial review

During the year under review there was a increase of £73,170 (2023: decrease of £53,031) on unrestricted funds and decrease of £10,060 (2023: introduced £87,281) on restricted funds.

Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus, the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements. The Charity's reserve policy is to hold reserves only to cover a period of 4 months administration costs. No additional reserves are intended to be held.

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to 4 month's expenditure. The trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised. This level of reserves has been maintained throughout the year.

Structure, governance and management

The charity was established by a charitable trust deed on 25th April 1998 in Belgium and registered as a Charitable Incorporated Organisation in the UK on 19th August 2015.

The trustees have had regard to the Charity Commission's guidance on public benefit.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

G Boyle	
J M M Domingos	
P Perez Librero	(Resigned 9 May 2024)
C P Likar	
A Moretti	
T Shaish	(Resigned 26 June 2024)
A S Butler	
B J Magennis	
K Wouters	
J Sinclair	(Appointed 26 June 2024)
E Ildal	(Appointed 26 June 2024)
C Molohan	(Appointed 26 June 2024)
C Bale	(Appointed 26 June 2024)

The following individuals were observer trustees during the period:

C Bale (elected in June 2024)
E Ildal (elected in June 2024)
C Molohan (elected in June 2024)
J Sinclair (elected in June 2024)

The following individuals retired during the period:

P Pérez Librero (retired in April 2024)
T Shaish (retired in June 2024)

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

The trustees' report was approved by the Board of Trustees.



J M M Domingos

Trustee

Date: Thursday 19 June 2025

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF PARKINSON'S EUROPE**

I report to the trustees on my examination of the financial statements of Parkinson's Europe (the charity) for the year ended 31 December 2024.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales., which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Louise Hallsworth, FCA

Baxter & Co
Chartered Accountants
Lynwood House, Crofton Road
Orpington
Kent
BR6 8QE

Dated: 20 June 2025

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

Current financial year		Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Total 2023 £
	Notes				
Income from:					
Donations and legacies	3	28,866	-	28,866	24,134
Charitable activities	4	470,303	3,832	474,135	553,452
Investments	5	693	-	693	478
Total income		499,862	3,832	503,694	578,064
Expenditure on:					
Charitable activities	6	409,470	14,574	424,044	528,345
Total expenditure		409,470	14,574	424,044	528,345
Net income/(expenditure)		90,392	(10,742)	79,650	49,719
Transfers between funds		(682)	682	-	-
Other recognised gains and losses:					
Other losses	12	(16,540)	-	(16,540)	(15,469)
Net movement in funds	8	73,170	(10,060)	63,110	34,250
Reconciliation of funds:					
Fund balances at 1 January 2024		48,463	87,281	135,744	101,494
Fund balances at 31 December 2024		121,633	77,221	198,854	135,744

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED)
INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

Prior financial year as restated		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
	Notes			
Income from:				
Donations and legacies	3	24,134	-	24,134
Charitable activities	4	455,211	98,241	553,452
Investments	5	478	-	478
Total income		479,823	98,241	578,064
Expenditure on:				
Charitable activities	6	517,385	10,960	528,345
Total expenditure		517,385	10,960	528,345
Net income/(expenditure)		(37,562)	87,281	49,719
Other recognised gains and losses:				
Other losses	12	(15,469)	-	(15,469)
Net movement in funds	8	(53,031)	87,281	34,250
Reconciliation of funds:				
Fund balances at 1 January 2023		101,494	-	101,494
Fund balances at 31 December 2023		48,463	87,281	135,744

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET**

AS AT 31 DECEMBER 2024

		2024		2023 as restated	
	Notes	£	£	£	£
Fixed assets					
Intangible assets	13		77,221		42,339
Current assets					
Debtors	14	2,500		56,726	
Cash at bank and in hand		275,369		221,438	
		277,869		278,164	
Creditors: amounts falling due within one year	15	(156,236)		(184,759)	
Net current assets			121,633		93,405
Total assets less current liabilities			198,854		135,744
The funds of the charity					
Restricted income funds	18		77,221		87,281
Unrestricted funds	19		121,633		48,463
			198,854		135,744


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2024.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on ...19 June 2025.



J M M Domingos
Trustee

Company registration number CE004367 (England and Wales)

Digita qui il testo

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Charity information

Parkinson Europe (formerly European Parkinson's Disease Association) is a Charitable Incorporated Organisation registered in the UK on 19 August 2015.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Charity's trust deed, the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024**

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Website	not amortised until completed
---------	-------------------------------

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities (if any). During the current and prior year there is no overdraft facility has been used on Parkinson's Europe's bank accounts.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.12 Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Donations and gifts	6,484	3,718
Membership fees	22,382	20,416
	<u>28,866</u>	<u>24,134</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

4 Income from charitable activities

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Charitable activities						
Core income	374,981	-	374,981	298,307	98,241	396,548
Project income	92,860	3,832	96,692	154,146	-	154,146
Other income	2,462	-	2,462	2,758	-	2,758
	<u>470,303</u>	<u>3,832</u>	<u>474,135</u>	<u>455,211</u>	<u>98,241</u>	<u>553,452</u>

5 Income from investments

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Interest receivable	<u>693</u>	<u>478</u>

6 Expenditure on charitable activities

	Charitable activities 2024 £	Charitable activities 2023 £ as restated
Direct costs		
Member organisation and board meetings	-	9,181
Advocacy communication and project development	13,094	76,604
Funded projects	21,146	43,313
Other direct costs	20	7,140
Freelancer costs	57,147	111,258
	<u>91,407</u>	<u>247,496</u>
Share of support and governance costs (see note 7)		
Support	319,706	274,625
Governance	12,931	6,224
	<u>424,044</u>	<u>528,345</u>
Analysis by fund		
Unrestricted funds	409,470	517,385
Restricted funds	14,574	10,960
	<u>424,044</u>	<u>528,345</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

6 Expenditure on charitable activities

(Continued)

Included within share of supports costs are wages and salary costs amounting to £13,791 (2023: £10,536) directly attributable to member organisation, board meetings and advocacy in addition to the £13,798 (2023: £17,582) shown above, therefore the total spend for member organisation and board meetings in 2024 amounts to £27,589 (2023: £28,118).

7 Support costs allocated to activities

	2024	2023
	£	£
Staff costs	305,309	262,481
Technology costs	2,500	3,319
Bad debts	-	192
Bank charges	66	314
Bookkeeping costs	4,266	3,960
Other support costs	4,304	2,685
Travel costs	2,017	560
Insurance	1,244	1,114
Governance costs	12,931	6,224
	<u>332,637</u>	<u>280,849</u>
Analysed between:		
Charitable activities	<u>332,637</u>	<u>280,849</u>

8 Net movement in funds

2024
£

2023
£

The net movement in funds is stated after charging/(crediting):

Fees payable for the independent examination of the charity's financial statements	1,386	1,320
	<u>1,386</u>	<u>1,320</u>

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

10 Employees

The average monthly number of employees during the year was:

	2024	2023
	Number	Number
Administration	6	6
	<u>6</u>	<u>6</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

10 Employees **(Continued)**

Employment costs	2024	2023
	£	£
Wages and salaries	279,275	242,071
Social security costs	19,764	15,162
Other pension costs	6,270	5,248
	<u>305,309</u>	<u>262,481</u>

Last years employment costs were recharged to specific budget headings within the overall expenditure.

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2024	2023
	Number	Number
£60,000 - £70,0000	<u>1</u>	<u>1</u>

Remuneration of key management personnel

The key management personnel of the charity comprise the Trustees and the key management team as listed on page 1. The total amount of key management personnel benefits (including employer pension contributions and employer national insurance contributions) received by key management personnel for their services to the charity was £126,510 (2023: £139,882).

11 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

12 Other gains and losses

	Unrestricted funds	Unrestricted funds
	2024	2023
	£	£
Gains/(losses) upon:		
Foreign exchange	<u>16,540</u>	<u>15,469</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

13 Intangible fixed assets

	Website £
Cost	
At 1 January 2024	42,339
Additions - separately acquired	34,882
At 31 December 2024	77,221
Amortisation and impairment	
At 1 January 2024 and 31 December 2024	-
Carrying amount	
At 31 December 2024	77,221
At 31 December 2023	42,339

14 Debtors

	2024 £	2023 £
Amounts falling due within one year:		
Trade debtors	100	56,726
Prepayments and accrued income	2,400	-
	2,500	56,726

15 Creditors: amounts falling due within one year

	Notes	2024 £	2023 £
Other taxation and social security		4,842	5,047
Deferred income	16	96,133	113,674
Trade creditors		4,440	27,125
Other creditors		17,501	17,267
Accruals		33,320	21,646
		156,236	184,759

16 Deferred income

	2024 £	2023 £
Other deferred income	96,133	113,674

Deferred income is included in the financial statements as follows:

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

16 Deferred income

(Continued)

	2024	2023
	£	£
Deferred income is included within:		
Current liabilities	96,133	113,674
	<u> </u>	<u> </u>
Movements in the year:		
Deferred income at 1 January 2024	113,674	145,149
Released from previous periods	(113,674)	(145,149)
Resources deferred in the year	96,133	113,674
	<u> </u>	<u> </u>
Deferred income at 31 December 2024	96,133	113,674
	<u> </u>	<u> </u>

17 Retirement benefit schemes

	2024	2023
	£	£
Defined contribution schemes		
Charge to profit or loss in respect of defined contribution schemes	6,270	5,248
	<u> </u>	<u> </u>

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

18 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2024	Incoming resources	Resources expended	Transfers	At 31 December 2024
	£	£	£	£	£
Website	87,281	-	(10,449)	389	77,221
MDS event	-	3,832	(4,125)	293	-
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
	87,281	3,832	(14,574)	682	77,221
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
					as restated
Website	-	98,241	(10,960)	-	87,281
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>

The specific purpose for which the Restricted Funds are to be applied is for the development of the New Website and MDS Event.

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

19 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2024	Incoming resources	Resources expended	Transfers	Gains and losses	At 31 December 2024
	£	£	£	£	£	£
General funds	48,463	499,862	(409,470)	(682)	(16,540)	121,633
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Previous year:	At 1 January 2023	Incoming resources	Resources expended	Transfers	Gains and losses	At 31 December 2023
	£	£	£	£	£	£
General funds	101,494	479,823	(517,385)	-	(15,469)	48,463
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>

20 Analysis of net assets between funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £
At 31 December 2024:			
Intangible fixed assets	-	77,221	77,221
Current assets/(liabilities)	121,633	-	121,633
	<u> </u>	<u> </u>	<u> </u>
	121,633	77,221	198,854
	<u> </u>	<u> </u>	<u> </u>
	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Intangible fixed assets	-	42,339	42,339
Current assets/(liabilities)	48,463	44,942	93,405
	<u> </u>	<u> </u>	<u> </u>
	48,463	87,281	135,744
	<u> </u>	<u> </u>	<u> </u>

21 Related party transactions

There were no disclosable related party transactions during the year (2023 - none), other than those disclosed within the trustees note in note 9.

22 Prior year restatement

The prior year restatement was made to capitalise the Intangible fixed assets of £42,339 for the new website.

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)**

KEY REPORTS AND NOTES IN EURO EQUIVALENT AT THE YEAR END

These pages do not form part of the statutory financial statements

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
	2024	2024	2024	2024
	£	€	£	€
Income from:				
Donations and legacies	28,866	34,926	-	-
Charitable activities	470,303	569,030	3,832	4,636
Investment income	<u>693</u>	<u>838</u>	<u>-</u>	<u>-</u>
Total income	<u>499,862</u>	<u>604,794</u>	<u>3,832</u>	<u>4,636</u>
Expenditure on:				
Charitable activities	<u>409,470</u>	<u>495,426</u>	<u>14,574</u>	<u>17,633</u>
Net income / (expenditure)	90,392	109,367	(10,742)	(12,997)
Transfers between funds	(682)	(825)	682	825
Other recognised gains and losses				
Other currency revaluation gains or losses	-	2,713	-	4,886
Other gains / (losses)	<u>(16,540)</u>	<u>(20,012)</u>	<u>-</u>	<u>-</u>
Net movement in funds	73,170	91,243	(10,060)	(7,286)
Fund balances at 1 January 2024	<u>48,436</u>	<u>55,923</u>	<u>87,281</u>	<u>100,717</u>
Fund balances at 31 December 2024	<u>121,633</u>	<u>147,166</u>	<u>77,221</u>	<u>93,431</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

<i>Comparative information</i>	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
	2023	2023	2023	2023
	£	€	£	€
Income from:				
Donations and legacies	24,134	27,849	-	-
Charitable activities	455,211	525,284	98,241	113,364
Investment income	<u>478</u>	<u>552</u>	<u>-</u>	<u>-</u>
Total income	<u>479,823</u>	<u>553,685</u>	<u>98,241</u>	<u>113,364</u>
Expenditure on:				
Charitable activities	<u>517,385</u>	<u>597,029</u>	<u>10,960</u>	<u>12,647</u>
Net income / (expenditure)	(37,562)	(43,344)	87,281	100,717
Transfers between funds				
Other recognised gains and losses				
Other currency revaluation gains or losses	-	2,667	-	-
Other gains / (losses)	<u>(15,469)</u>	<u>(17,850)</u>	<u>-</u>	<u>-</u>
Net movement in funds	(53,031)	(58,527)	87,281	100,717
Fund balances at 1 January 2023	<u>101,494</u>	<u>114,450</u>	<u>-</u>	<u>-</u>
Fund balances at 31 December 2023	<u>48,463</u>	<u>55,923</u>	<u>87,281</u>	<u>100,717</u>

**PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
BALANCE SHEET (EURO)**

AS AT 31 DECEMBER 2024

	2024	2024	2023	2023
	£	€	£	€
Fixed assets				
Intangible assets	77,221	93,431	42,339	48,856
Current assets				
Debtors	2,500	3,025	56,726	65,458
Cash at bank and in hand	<u>275,369</u>	<u>333,175</u>	<u>221,438</u>	<u>255,525</u>
	277,869	336,200	278,164	320,983
Creditors: amounts falling due within one year	<u>(156,236)</u>	<u>(189,033)</u>	<u>(184,759)</u>	<u>(213,200)</u>
Net current assets	<u>121,633</u>	<u>147,166</u>	<u>93,405</u>	<u>107,783</u>
Total assets less current liabilities	<u>198,854</u>	<u>240,598</u>	<u>135,744</u>	<u>156,640</u>
Income funds				
Restricted funds	77,221	93,431	87,281	100,717
Unrestricted funds	<u>121,633</u>	<u>147,166</u>	<u>48,463</u>	<u>55,923</u>
Total funds	<u>198,854</u>	<u>240,598</u>	<u>135,744</u>	<u>156,640</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

INCOME	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
	2024	2024	2024	2024
	£	€	£	€
Donations and legacies				
Donations and gifts	6,484	7,845	-	-
Membership fees	<u>22,382</u>	<u>27,080</u>	<u>-</u>	<u>-</u>
	<u>24,134</u>	<u>27,849</u>	<u>-</u>	<u>-</u>
Charitable activities				
Core income	374,981	453,698	-	-
Project income	92,860	112,353	3,832	4,636
Other income	<u>2,462</u>	<u>2,979</u>	<u>-</u>	<u>-</u>
	<u>470,303</u>	<u>569,030</u>	<u>3,832</u>	<u>4,636</u>
Investment income				
Interest receivable	<u>693</u>	<u>838</u>	<u>-</u>	<u>-</u>
INCOME	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
Comparative information	2023	2023	2023	2023
	£	€	£	€
Donations and legacies				
Donations and gifts	3,781	4,290	-	-
Membership fees	<u>20,416</u>	<u>23,559</u>	<u>-</u>	<u>-</u>
	<u>24,134</u>	<u>27,849</u>	<u>-</u>	<u>-</u>
Charitable activities				
Core income	298,307	344,227	98,241	113,364
Project income	154,146	177,874	-	-
Other income	<u>2,758</u>	<u>3,183</u>	<u>-</u>	<u>-</u>
	<u>455,211</u>	<u>525,284</u>	<u>98,241</u>	<u>113,364</u>
Investment income				
Interest receivable	<u>478</u>	<u>552</u>	<u>-</u>	<u>-</u>

This page does not form part of the statutory financial statements

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

EXPENDITURE	Unrestricted funds 2024 £	Unrestricted funds 2024 €	Restricted funds 2024 £	Restricted funds 2024 €
Charitable activities				
Direct costs				
Member organisation and board meetings	-	-	-	-
Advocacy communication and project development	13,094	15,843	-	-
Funded projects	18,785	22,728	2,361	2,857
Other direct costs	20	24	-	-
Freelancer costs	<u>56,319</u>	<u>68,142</u>	<u>828</u>	<u>1,001</u>
	<u>88,218</u>	<u>106,737</u>	<u>3,189</u>	<u>3,858</u>
Support costs				
Staff costs	293,924	355,625	11,385	13,775
Technology costs	2,500	3,025	-	-
Bank charges	66	80	-	-
Bookkeeping costs	4,266	5,162	-	-
Other support costs	4,304	5,208	-	-
Travel costs	2,017	2,440	-	-
Insurance	1,244	1,505	-	-
Governance costs	<u>12,931</u>	<u>15,645</u>	<u>-</u>	<u>-</u>
	<u>321,252</u>	<u>388,690</u>	<u>11,385</u>	<u>13,775</u>

PARKINSON'S EUROPE
(FORMERLY EUROPEAN PARKINSON'S DISEASE ASSOCIATION)
NOTES TO THE FINANCIAL STATEMENTS (EURO)

FOR THE YEAR ENDED 31 DECEMBER 2024

EXPENDITURE	Unrestricted funds	Unrestricted funds	Restricted funds	Restricted funds
<i>Comparative information</i>	2023	2023	2023	2023
	£	€	£	€
Charitable activities				
Direct costs				
Member organisation and board meetings	9,181	10,594	-	-
Advocacy communication and project development	76,604	88,396	42,339	48,856
Funded projects	43,313	49,980	-	-
Other direct costs	7,140	8,239	-	-
Freelancer costs	<u>102,672</u>	<u>118,477</u>	<u>8,586</u>	<u>9,908</u>
	<u>238,910</u>	<u>275,687</u>	<u>50,925</u>	<u>58,764</u>
Support costs				
Staff costs	260,138	300,182	2,343	2,704
Technology costs	3,288	3,794	-	-
Bank charges	314	362	-	-
Bookkeeping costs	2,685	3,098	-	-
Other support costs	2,685	3,098	-	-
Travel costs	560	646	-	-
Insurance	1,114	1,285	-	-
Governance costs	<u>6,224</u>	<u>7,182</u>	<u>-</u>	<u>-</u>
	<u>278,475</u>	<u>321,342</u>	<u>2,374</u>	<u>2,739</u>